5000272026-04-012026-06-305000272026-06-305000272026-04-012026-06-30in-capmkt:OtherExpenses1Member5000272026-04-012026-06-30in-capmkt:OtherExpenses2Member5000272026-04-012026-06-30in-capmkt:ReportableSegments1Member5000272026-04-012026-06-30in-capmkt:ReportableSegments2Member5000272026-04-012026-06-30in-capmkt:ReportableSegments3Member5000272026-04-012026-06-30in-capmkt:ReportableSegments1Member5000272026-04-012026-06-30in-capmkt:ReportableSegments2Member5000272026-04-012026-06-30in-capmkt:ReportableSegments3Member5000272026-04-012026-06-30in-capmkt:ReportableSegments1Member5000272026-06-30in-capmkt:ReportableSegments1Member5000272026-04-012026-06-30in-capmkt:ReportableSegments2Member5000272026-06-30in-capmkt:ReportableSegments2Member5000272026-04-012026-06-30in-capmkt:ReportableSegments3Member5000272026-06-30in-capmkt:ReportableSegments3Member5000272026-04-012026-06-30in-capmkt:ReportableSegments1Member5000272026-06-30in-capmkt:ReportableSegments1Member5000272026-04-012026-06-30in-capmkt:ReportableSegments2Member5000272026-06-30in-capmkt:ReportableSegments2Member5000272026-04-012026-06-30in-capmkt:ReportableSegments3Member5000272026-06-30in-capmkt:ReportableSegments3Member5000272026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15000272026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25000272026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss15000272026-04-012026-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares500027ATULNOTLISTEDINE100A01010ATUL LIMITEDMain BoardEquity2026-04-012027-03-312026-07-242026-06-25INRCroresQuarterlyFirst quarterMulti segment2026-07-2410:15:002026-07-2414:15:00Declaration of unmodified opinionfalsefalseNil debt hence not applicable2026-04-012026-06-30UnauditedStandalone15886000000263100000161491000009859400000237500000-16675000001066200000730000052070000034270000001345060000026985000000269850000065570000026500000682200000-6000000201030000000002010300000120340000032137000002944000001068.2868.280068.2868.28Standalone unaudited financial results for the quarter ended on June 30, 2026 <br /> Notes: <br /> <br /> 1. These results have been prepared in accordance with the Indian Accounting Standard (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. <br /> <br /> 2. These results have been reviewed and recommended for adoption by the Audit Committee in its meeting held on July 23, 2026 and approved by the Board of Directors in its meeting held on July 24, 2026. The Statutory Auditors have carried out a limited review of the standalone unaudited financial results for the quarter ended on June 30, 2026. Their limited review report does not have any modification. <br /> <br /> 3. The Company publishes the standalone financial results along with the consolidated financial results. In accordance with the Ind AS 108, 'Operating Segments', the Company has disclosed the segment information in the consolidated financial results and therefore no separate disclosure on segment information is given in the standalone financial results for the quarter ended on June 30, 2026. <br /> <br /> 4. Employee benefit expenses for the quarter ended March 31, 2026, include the impact of the reassessment of past service cost on gratuity and the remeasurement of leave encashment due to implementation of the new labour code, consequently a gain due to reversal of excess provision of Rs. 24.38 cr was recognised for the quarter ended on March 31, 2026. <br /> <br /> 5. The figures for the quarter ended on March 31, 2026 are the balancing figures between audited figures for the full financial year and the published year-to-date figures up to the third quarter. <br /> Power, fuel and water1595700000Other Expenses1831300000Life Science Chemicals4692300000Performance and Other Chemicals14274400000Others2598000001922650000074700000018479500000Life Science Chemicals927800000Performance and Other Chemicals2398300000Others67700000339380000040200000-1147000003468300000Life Science Chemicals14245300000Performance and Other Chemicals41667300000Others2516900000584295000002685470000085284200000Life Science Chemicals3457200000Performance and Other Chemicals10699100000Others21940000014375700000418920000018564900000Fair value of equity instruments through other comprehensive income1420800000Remeasurement gain | loss on defined benefit plans-416000001379200000175800000Effective portion of gain | loss on cashflow hedges0001203400000UnauditedtrueDeloitte Haskins and Sells LLPtrue2027-07-31